Galmed Pharmaceuticals Ltd.

NasdaqCM:GLMD Voorraadrapport

Marktkapitalisatie: US$4.9m

Galmed Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Allen Baharaff

Algemeen directeur

US$1.4m

Totale compensatie

Percentage CEO-salaris40.6%
Dienstverband CEO24.8yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijn7.7yrs
Gemiddelde ambtstermijn bestuur8.9yrs

Recente managementupdates

Recent updates

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

May 16
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Jan 06
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Galmed GAAP EPS of -$0.15 beats by $0.09

Aug 04

Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky

May 03
Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Jan 15
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Oct 02
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?

May 20
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?

Galmed gets greenlight for late-stage Aramchol NASH trial in China

May 03

What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?

Feb 04
What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?

We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth

Dec 06
We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth

Galmed EPS misses by $0.02

Nov 12

Analyse CEO-vergoeding

Hoe is Allen Baharaff's beloning veranderd ten opzichte van Galmed Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$6m

Mar 31 2024n/an/a

-US$6m

Dec 31 2023US$1mUS$551k

-US$7m

Sep 30 2023n/an/a

-US$8m

Jun 30 2023n/an/a

-US$11m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$1mUS$605k

-US$18m

Sep 30 2022n/an/a

-US$23m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$30m

Dec 31 2021US$3mUS$632k

-US$32m

Sep 30 2021n/an/a

-US$35m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$1mUS$503k

-US$29m

Sep 30 2020n/an/a

-US$27m

Jun 30 2020n/an/a

-US$24m

Mar 31 2020n/an/a

-US$23m

Dec 31 2019US$1mUS$486k

-US$20m

Sep 30 2019n/an/a

-US$16m

Jun 30 2019n/an/a

-US$12m

Mar 31 2019n/an/a

-US$11m

Dec 31 2018US$2mUS$384k

-US$10m

Sep 30 2018n/an/a

-US$10m

Jun 30 2018n/an/a

-US$12m

Mar 31 2018n/an/a

-US$12m

Dec 31 2017US$1mUS$384k

-US$12m

Compensatie versus markt: De totale vergoeding ($USD 1.36M ) Allen } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 653.78K ).

Compensatie versus inkomsten: De vergoeding van Allen is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Allen Baharaff (59 yo)

24.8yrs

Tenure

US$1,356,184

Compensatie

Mr. Allen Baharaff has been the Chief Executive Officer of Galmed Pharmaceuticals Ltd. since January 2012 and has been its President since March 2015. Mr. Baharaff co-founded the Galmed Pharmaceuticals Ltd...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Allen Baharaff
Co-Founder24.8yrsUS$1.36mgeen gegevens
Doron Cohen
Chief Financial Officer2.8yrsUS$273.81k0.0011%
$ 55.2
Guy Nehemya
COO & Data Protection Officer7.7yrsUS$374.78k0.0021%
$ 100.6
Yohai Stenzler
Chief Accounting Officer2.8yrsUS$378.32k0.0021%
$ 100.6
Liat Hayardeny
Chief Scientific Officer8.2yrsUS$114.69k0%
$ 0
Tali Gorfine
Medical Consultant7.7yrsUS$382.51kgeen gegevens

7.7yrs

Gemiddelde duur

55.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van GLMD is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.7 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Allen Baharaff
Co-Founderno dataUS$1.36mgeen gegevens
David Sidransky
Lead Independent Director10.4yrsgeen gegevens0.0028%
$ 136.2
Carol Brosgart
Independent Director7.4yrsgeen gegevens0%
$ 0
José Mato de la Paz
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Scott L. Friedman
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Arun Sanyal
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Vlad Ratziu
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Shmuel Nir
Independent Director17.8yrsgeen gegevens0.0028%
$ 136.2
Amir Poshinski
Independent Director4.4yrsgeen gegevens0%
$ 0
Shomron Ben-Horin
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens

8.9yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GLMD wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.9 jaar).